AccessibilityHelpAbout Us
Herborium Group logo

Herborium Group(OTC) HBRM

Market Cap$1.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-100%
5 Year-89%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Herborium Group last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-10
Herborium Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-09-03
1 month+0%USD 0.002026-08-11
3 month+9,900%USD 0.002026-06-12
Year to date+100%USD 0.002025-12-31
1 year+0%USD 0.002025-09-10
3 year+0%USD 0.002023-09-11
5 year-88.89%USD 0.002021-09-10
Since inception-100%USD 60.002006-09-19

Herborium Group Financials at a Glance

Market Cap

$1.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$786.95K

Net Income (TTM)

-$230.74K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-3.05 (Low)

Price

$0.00

Volume

595,961

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Jan 29, 2025

HBRM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Herborium Group

Herborium Group, Inc. specializes in botanical therapeutics, focusing on the development and commercialization of plant-based medicinal products. The company offers a range of solutions targeting dermatological issues, sexual health, and energy enhancement.

Products and Services
  • AcnEase: Herbal treatment for hormonal acne and Rosacea
  • Lasting Energy: Supplement to combat hangover effects and fatigue
  • ProstAid: Natural remedy for Benign Prostate Hyperplasia (BPH)
Growth Outlook
  • Recent revenue of $29,250 in Q2 2026 indicates potential for recovery
  • Gross profit margin of 52.1% in Q2 2026 shows strong product demand
  • Expansion into the UK and mainland Europe enhances market reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of $1,000,000 reflects steady sales growth
  • Operating income margin of -91.4% in Q2 2026 suggests room for operational improvements
  • Cash flow from operations of $101,420 in Q4 2023 indicates positive cash generation
Herborium Group, Inc. operates in the healthcare sector, specifically within the drug manufacturing industry, focusing on specialty and generic products. The company has developed a unique portfolio of herbal solutions that cater to various health needs, including skin conditions and sexual health. The recent financial performance indicates a potential turnaround, with a notable gross profit margin and positive cash flow from operations. The company's strategic expansion into international markets may further enhance growth opportunities. Investors may find Herborium Group, Inc. an intriguing option within the botanical therapeutics space.
AI Generated • Aug 24, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

6

CEO

Agnes Paulina Olszewski, PhD, MBA

Website

www.herborium.com

Headquarters

Sugar Land, TX 77478, US

HBRM Financials

Key Financial Metrics (TTM)

Gross Margin

61.02%

Operating Margin

-36.90%

Net Income Margin

-29.32%

Return on Equity

6.01%

Return on Capital

N/A

Return on Assets

-307.24%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.42B

Volume

595.96K

Avg. Volume

651.67K

Financials (TTM)

Gross Profit

$480.20K

Operating Income

-$290.35K

EBITDA

-$290.35K

Operating Cash Flow

$197.07K

Capital Expenditure

$0.00

Free Cash Flow

$197.07K

Cash & ST Invst.

$3.50K

Total Debt

$1.07M

Herborium Group Performance Analysis

Herborium Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-11-30USD 1,133,1007.8%
20232023-11-30USD 1,119,420-1.2%
20242024-11-30USD 1,051,000-6.1%
20252025-11-30USD 788,250-25.0%
Herborium Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-08-31-14.3%
Q42025-11-30615.4%
Q12026-02-28-37.2%
Q22026-05-31-89.1%
Herborium Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-11-30USD 0.00N/A
20232023-11-30USD 0.00N/A
20242024-11-30USD 0.00N/A
20252025-11-30USD 0.00N/A
Herborium Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-08-31N/A
Q42025-11-30N/A
Q12026-02-28N/A
Q22026-05-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$29.25K

-58.2%

Gross Profit

$15.25K

-62.7%

Gross Margin

52.14%

N/A

Market Cap

$1.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$570.95K

N/A

Employees

2

N/A

Net Income

-$26.75K

-41.5%

EBITDA

-$26.75K

-41.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$3.50K

-50.0%

Total Debt

$1.07M

-8.6%

Accounts Receivable

$4.85K

-50.3%

Inventory

$2.50K

-75.0%

Long Term Debt

$667.50K

+0.0%

Short Term Debt

$401.59K

-19.9%

Return on Assets

-3.07%

N/A

Return on Invested Capital

13.38%

N/A

Free Cash Flow

-$5.60K

-103.4%

Operating Cash Flow

-$5.60K

-103.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MJNAMedical Marijuana, Inc.
$0.00-50.00%
PCYNProcyon Corporation
$0.25+0.00%
EDXCEndexx Corporation
$0.00+0.00%
BMCSBioTech Medics, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
KHCKraft Heinz
$24.60+0.01%
ACVAACV Auctions
$10.41+0.44%
TNONTenon Medical
$5.93+0.12%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$19.16+0.03%

Questions About HBRM

What is the current price of Herborium Group?

Herborium Group is trading at $0.00 per share.

What is the 52-week range for Herborium Group?

Over the past 52 weeks, Herborium Group has traded between $0.00 and $0.00.

How much debt does Herborium Group have?

As of the most recent reporting period, Herborium Group reported total debt of $1.07M.

How much cash does Herborium Group have on hand?

Herborium Group reported $3.50K in cash and cash equivalents in its most recent financial results.

What is Herborium Group’s dividend yield?

Herborium Group does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services